Avapritinib for Cutaneous Mastocytosis

Authors

  • Hannah Lee
  • Tian Li
  • Joshua Wisell
  • Jeffrey Schowinsky
  • William A. Robinson Department of Oncology, University of Colorado School of Medicine, 12801 E. 17 Ave L18-8400, Aurora, CO 80045, USA

DOI:

https://doi.org/10.2340/00015555-3709

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Erben P, Schwaab J, Metzgeroth G, Horny HP, Jawhar M, Sotlar K, et al. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol 2014; 93: 81-88.

DOI: https://doi.org/10.1007/s00277-013-1964-1

Severino M, Chandesris MO, Barete S, Tournier E, Sans B, Laurent C, et al. Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. J Am Acad Dermatol 2016; 74: 885-891 e881.

DOI: https://doi.org/10.1016/j.jaad.2015.10.050

Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420-1427.

DOI: https://doi.org/10.1182/blood-2016-09-731893

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med 2017; 9: eaao1690.

DOI: https://doi.org/10.1126/scitranslmed.aao1690

Drummond MW, DeAngelo DJ, Deininger MW, Radia D, Quiery AT, Hexner EO, et al. Preliminary safety and clinical activity in a Phase 1 study of Blu-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (SM). Blood 2016; 128: 477-477.

DOI: https://doi.org/10.1182/blood.V128.22.477.477

Heinrich MC, Jones RL, Mehren Mv, Bauer S, Kang Y-K, Schoffski P, et al. Clinical activity of avapritinib in ? fourth-line (4L+) and PDGFRA Exon 18 gastrointestinal stromal tumors (GIST). J Clin Oncol 2019; 37: 11022-11022.

DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.11022

Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol 2020; 21: 935-946.

DOI: https://doi.org/10.1016/S1470-2045(20)30269-2

Published

2021-01-05

How to Cite

Lee, H., Li, T., Wisell, J., Schowinsky, J., & Robinson, W. A. (2021). Avapritinib for Cutaneous Mastocytosis. Acta Dermato-Venereologica, 101(1), adv00362. https://doi.org/10.2340/00015555-3709

Issue

Section

Short Communication

Categories